IRadimed Corporation (IRMD) is a Healthcare stock trading at $86.75 (as of 2026-08-20), with a market capitalization of $1.11B and a trailing P/E of 49.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
IRadimed develops, manufactures, markets, and distributes MRI-compatible medical devices, including MRI-compatible infusion pumps and patient vital signs monitoring systems, and it also sells related accessories and services that generate revenue from device sales plus disposables and services.
The profit engine links hospital adoption of MRI-compatible device systems to follow-on revenue streams from disposables, services, and other related products.
| Devices | $0.0B |
| Disposables,Svc&Other | $0.0B |
Business quality (Strong): High reported margins (gross margin 76.5%, operating margin 32.9%) are a strength, but the operating picture is limited here because the latest revenue is shown as 0.0B (with very small segment values provided), and the most concrete operating metric is a specific program unit shipment count.
Valuation: At 51× earnings, IRMD trades 59% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $86.75 |
| Market Cap | $1.11B |
| P/E Ratio | 49.5 |
| EV / EBITDA | 36.0 |
| Price / Book | 10.90 |
| Price / Sales | 12.96 |
| FCF Yield | 3.7% |
| DCF Value (model) | $73.94 |
| DCF Upside vs Price | -14.8% |
| Revenue (TTM) | $83.81M |
| Net Margin | 26.8% |
| Revenue Growth (YoY) | 14.4% |
| EPS Growth (YoY) | 16.4% |
| FCF Growth (YoY) | -2.5% |
| Altman Z-Score | 50.17 (safe) |
| Stock P/E | 49.5 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| vs Sector | 129.0% |
| vs Industry | 50.4% |
| Top Institutional Holder | BlackRock, Inc. ($93.16M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Roger E. Susi |
| Employees | 160 |
| Country | US |
| IPO Date | 2014-07-16 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.